Synairgen is a University spin-off and public limited company (plc) [ 2] [ 1] [ 3] working in drug discovery and biotechnology . It was founded in 2003 by University of Southampton professors Stephen Holgate ,[ 4] Donna E. Davies and Ratko Djukanovic [Wikidata ] . The company is developing an inhaled formulation of interferon -beta for severe viral respiratory diseases including COVID-19 .[ 5] [ 6] [ 7] [ 8] [ 9]
Richard Marsden was appointed chief executive officer in September 2009.[ 10]
^ a b Anon (2016). "SYNAIRGEN PLC" . companieshouse.gov.uk . London: Companies House .
^ Anon (2020). "SYNAIRGEN PLC SNG Stock" . londonstockexchange.com . London Stock Exchange .
^ Rowlatt, Justin (July 20, 2020). "Covid treatment trial described as 'breakthrough' " . bbc.co.uk . BBC News .
^ "Clean Air Champion Professor Sir Stephen Holgate receives Knighthood" . Clean Air Programme . 2021-12-07. Retrieved 2022-02-03 .
^ "- Synairgen" . synairgen.com . Retrieved 2022-02-03 .
^ Neate, Rupert (July 24, 2020). " 'Major' breakthrough in Covid-19 drug makes UK professors millionaires" . The Guardian .
^ Anon (2020). "Expert reaction to announcement by Synairgen that their drug SNG001 has had positive results in initial trials on COVID-19 patients" . Science Media Centre .
^ Donnelly, Laura (July 20, 2020). "Coronavirus drug hailed as game-changer after trial finds it cuts chances of severe illness" . telegraph.co.uk . Daily Telegraph .
^ Holgate, Stephen; Agusti, Alvar; Strieter, Robert M.; Anderson, Gary P.; Fogel, Robert; Bel, Elisabeth; Martin, Thomas R.; Reiss, Theodore F. (2015). "Drug development for airway diseases: looking forward". Nature Reviews Drug Discovery . 14 (6): 367–368. doi :10.1038/nrd4645 . ISSN 1474-1776 . PMID 26000726 . S2CID 8539798 .
^ "SNG: Synairgen PLC Stock Price Quote - London - Bloomberg" . bloomberg.com . Retrieved 2022-02-03 .